vs
Side-by-side financial comparison of Strata Critical Medical, Inc. (SRTA) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $22.7M, roughly 1.3× Strata Critical Medical, Inc.). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-10.2M). Over the past eight quarters, SYPRIS SOLUTIONS INC's revenue compounded faster (-7.7% CAGR vs -33.6%).
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
SRTA vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.7M | $30.3M |
| Net Profit | — | $-3.9M |
| Gross Margin | -0.9% | 4.6% |
| Operating Margin | -18.4% | -10.9% |
| Net Margin | — | -12.9% |
| Revenue YoY | 361.2% | -9.5% |
| Net Profit YoY | — | -2992.6% |
| EPS (diluted) | $-0.11 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.7M | $30.3M | ||
| Q3 25 | $49.3M | $28.7M | ||
| Q2 25 | $70.8M | $31.4M | ||
| Q1 25 | $54.3M | $29.5M | ||
| Q4 24 | $-8.7M | $33.4M | ||
| Q3 24 | $36.1M | $35.7M | ||
| Q2 24 | $67.9M | $35.5M | ||
| Q1 24 | $51.5M | $35.6M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | $57.4M | $517.0K | ||
| Q2 25 | $-3.7M | $-2.1M | ||
| Q1 25 | $-3.5M | $-899.0K | ||
| Q4 24 | — | $135.0K | ||
| Q3 24 | $-2.0M | $390.0K | ||
| Q2 24 | $-11.3M | $16.0K | ||
| Q1 24 | $-4.2M | $-2.2M |
| Q4 25 | -0.9% | 4.6% | ||
| Q3 25 | 23.6% | 7.2% | ||
| Q2 25 | 25.1% | 8.2% | ||
| Q1 25 | 22.1% | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | 20.8% | 16.8% | ||
| Q2 24 | 24.1% | 15.9% | ||
| Q1 24 | 19.7% | 8.1% |
| Q4 25 | -18.4% | -10.9% | ||
| Q3 25 | -11.4% | -6.1% | ||
| Q2 25 | -7.0% | -4.6% | ||
| Q1 25 | -14.0% | -0.4% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | -19.7% | 4.8% | ||
| Q2 24 | -17.9% | 3.6% | ||
| Q1 24 | -19.2% | -3.9% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | 116.5% | 1.8% | ||
| Q2 25 | -5.3% | -6.5% | ||
| Q1 25 | -6.4% | -3.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -5.4% | 1.1% | ||
| Q2 24 | -16.7% | 0.0% | ||
| Q1 24 | -8.2% | -6.2% |
| Q4 25 | $-0.11 | $-0.17 | ||
| Q3 25 | $0.70 | $0.02 | ||
| Q2 25 | $-0.05 | $-0.09 | ||
| Q1 25 | $-0.04 | $-0.04 | ||
| Q4 24 | $-0.11 | $0.00 | ||
| Q3 24 | $-0.03 | $0.02 | ||
| Q2 24 | $-0.15 | $0.00 | ||
| Q1 24 | $-0.06 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $279.1M | $17.8M |
| Total Assets | $325.5M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.0M | — | ||
| Q3 25 | $22.8M | — | ||
| Q2 25 | $58.8M | — | ||
| Q1 25 | $34.8M | — | ||
| Q4 24 | $18.4M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $26.3M | — | ||
| Q1 24 | $36.8M | — |
| Q4 25 | $279.1M | $17.8M | ||
| Q3 25 | $283.0M | $20.0M | ||
| Q2 25 | $223.1M | $18.7M | ||
| Q1 25 | $219.7M | $19.0M | ||
| Q4 24 | $221.9M | $19.6M | ||
| Q3 24 | $233.5M | $18.2M | ||
| Q2 24 | $229.4M | $19.0M | ||
| Q1 24 | $236.6M | $20.8M |
| Q4 25 | $325.5M | $107.8M | ||
| Q3 25 | $335.1M | $112.5M | ||
| Q2 25 | $257.9M | $105.8M | ||
| Q1 25 | $250.6M | $110.2M | ||
| Q4 24 | $256.7M | $119.4M | ||
| Q3 24 | $282.9M | $121.6M | ||
| Q2 24 | $280.3M | $124.2M | ||
| Q1 24 | $282.8M | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.3M | $-1.1M |
| Free Cash FlowOCF − Capex | $-10.2M | $-1.5M |
| FCF MarginFCF / Revenue | -44.7% | -5.0% |
| Capex IntensityCapex / Revenue | 8.1% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-58.5M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.3M | $-1.1M | ||
| Q3 25 | $-37.3M | $-178.0K | ||
| Q2 25 | $-3.1M | $1.1M | ||
| Q1 25 | $-246.0K | $-5.5M | ||
| Q4 24 | $-1.8M | $2.3M | ||
| Q3 24 | $6.4M | $-4.8M | ||
| Q2 24 | $8.4M | $6.2M | ||
| Q1 24 | $-15.6M | $-1.7M |
| Q4 25 | $-10.2M | $-1.5M | ||
| Q3 25 | $-40.1M | $-390.0K | ||
| Q2 25 | $-5.4M | $941.0K | ||
| Q1 25 | $-2.9M | $-5.5M | ||
| Q4 24 | $-6.3M | $1.9M | ||
| Q3 24 | $-3.0M | $-4.9M | ||
| Q2 24 | $-7.7M | $6.0M | ||
| Q1 24 | $-16.4M | $-2.0M |
| Q4 25 | -44.7% | -5.0% | ||
| Q3 25 | -81.4% | -1.4% | ||
| Q2 25 | -7.6% | 3.0% | ||
| Q1 25 | -5.3% | -18.8% | ||
| Q4 24 | 72.7% | 5.7% | ||
| Q3 24 | -8.2% | -13.8% | ||
| Q2 24 | -11.4% | 16.8% | ||
| Q1 24 | -31.8% | -5.7% |
| Q4 25 | 8.1% | 1.3% | ||
| Q3 25 | 5.7% | 0.7% | ||
| Q2 25 | 3.2% | 0.5% | ||
| Q1 25 | 4.8% | 0.0% | ||
| Q4 24 | -52.6% | 1.2% | ||
| Q3 24 | 25.8% | 0.4% | ||
| Q2 24 | 23.8% | 0.5% | ||
| Q1 24 | 1.6% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | -0.65× | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
